Full-Time

Software Engineer

Core Infrastructure

Posted on 1/27/2026

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharma partners

No salary listed

San Mateo, CA, USA

In Person

Category
Software Engineering (1)
Required Skills
Bash
Kubernetes
Python
AWS
Terraform
Google Cloud Platform
Requirements
  • 5+ years of experience building and maintaining cloud infrastructure at scale, e.g. within AWS or GCP
  • Proficient with Python, Bash, Terraform, Ray and Kubernetes
  • Ideally, experience building and maintaining compute clusters running distributed ML training jobs with 1,000+ GPUs
  • Nice to have: hands-on experience with physical hardware + datacenter management
Responsibilities
  • Work on our infrastructure team to maintain and grow our multi-cloud compute infrastructure that supports our ML model training, computational chemistry research, and ongoing drug discovery efforts
  • Build out our configuration and procedures for monitoring, resource allocation, and deployment automation, as we continue to grow our autoscaling compute clusters to handle larger workloads
  • Work on orchestration scheduling framework to increase our execution throughput, reliability, and compute utilization across heterogeneous pipelines

Genesis Therapeutics uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. Its platform combines 3D spatial graph modeling with advanced molecular simulation to generate potential drug candidates and to explore new chemical spaces and protein targets. They operate on a business-to-business model, partnering with biotech and pharma companies and earning upfront payments and milestones from collaborations (for example, a Lilly deal worth up to $670 million). Their goal is to deliver AI-generated drug ideas and validated leads to collaborators, accelerating the path from target to therapeutic candidate.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$400.1M

Headquarters

Burlingame, California

Founded

2019

Your Connections

People at Genesis Therapeutics who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Incyte's 2025 collaboration brought $30 million upfront and up to $885 million total.
  • Partnerships with Gilead, Eli Lilly, Genentech, and Incyte validate Genesis' platform.
  • NVIDIA backing strengthens compute access for 3D molecular modeling and foundation-model training.

What critics are saying

  • Gilead retains exclusive development and commercialization rights, limiting Genesis' downstream economics.
  • Big pharma partners can internalize successful workflows and replace Genesis after validation.
  • Foundation-model spending and compute costs can outpace partnership revenue, pressuring burn.

What makes Genesis Therapeutics unique

  • GEMS combines language models, diffusion models, and physical ML simulations.
  • Genesis pairs frontier AI researchers with experienced drug hunters.
  • Founded from Vijay Pande's Stanford lab in 2019, it has deep scientific roots.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

6%

2 year growth

6%
Business News Today
Dec 3rd, 2025
Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard?

Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard? Genesis Molecular AI hires Meta's Llama leader Sergey Edunov to lead foundation models. Discover how this move strengthens its AI drug discovery platform. Genesis Molecular AI, the foundation model-driven drug design firm formerly known as Genesis Therapeutics, has appointed Sergey Edunov as Senior Vice President of Foundation Models. The executive hire marks a strategic inflection point as the company prepares to scale its GEMS platform and unveil new generative model research at the NeurIPS 2025 conference. Sergey Edunov is best known for his leadership role in developing Meta Platforms' Llama 2 and Llama 3 large language models. He brings over two decades of software engineering and AI research experience, having previously served as Senior Director of AI Research in Meta's generative AI division. His arrival at Genesis Molecular AI signals the firm's ambition to compete at the highest levels of foundation model development applied to molecular design.

Latest Nigerian News
Aug 7th, 2025
Genesis Therapeutics raises $52M for AI drug discovery

Genesis Therapeutics has successfully raised a $52 million A round to advance its AI-focused drug discovery mission. The company employs a novel simulation approach and a cross-disciplinary team to efficiently explore the vast array of potential medicinal molecules.

Delaware Business Times
May 28th, 2025
Incyte aims to accelerate drug research with AI collaboration

Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.

Fierce Biotech
Feb 20th, 2025
Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.

Genetic Engineering and Biotechnology News
Dec 18th, 2024
Genesis Therapeutics Secures Nvidia Investment Boost

Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.

INACTIVE